Alterity Therapeutics Files Application for Quotation of Securities (ATH)

Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K on July 9, 2026, with the SEC. The filing serves as a report of a foreign private issuer and includes an application for the quotation of securities (Exhibit 99.1) under the ticker ATH. The document indicates that the company is seeking to list or quote additional securities, which is being incorporated by reference into several of its existing Registration Statements on Form S-8 and Form F-3. These registration statements typically relate to employee stock incentive plans and shelf registrations for future capital raises. The filing was signed by Julian Babarczy, the Chairman of Alterity Therapeutics. Beyond the administrative notification of the application for quotation, the filing does not provide specific details regarding the quantity of securities or the pricing associated with this action. This filing is a standard regulatory requirement for foreign entities listed on U.S. exchanges when modifying their equity structure.